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Objective.Toevaluate andcomparenoncontinentandcontinenturinarydiversionafterradicalcystectomyinpatientswithbladder
cancer. Methods. A total of 301 patients submitted to radical cystectomy at the Charit´ e-University Hospital Berlin from 1993 to
2007 including 146 with an ileal conduit and 115 with an ileal neobladder. Clinical and pathological data as well as oncological
outcome were retrospectively analyzed and compared. Quality of life was analyzed using the EORTC QLQ-C30 and BLM30
questionnaires. Results. 69.1% and 69.6% of all patients who received an ileal conduit and ileal neobladder, respectively, developed
early complications. The two groups diﬀered signiﬁcantly concerning the occurrence of postoperative ileus (P = 0.02) favoring
patients who received an ileal conduit but not with regard to any other early-onset complication evaluated. Patients with ileal
neobladder had a signiﬁcantly better global health status and quality of life (P = 0.02), better physical functioning (P = 0.02),
but also a higher rate of diarrhoea (P = 0.004). Conclusion. Cystectomy with any type of diversion remains a complication-prone
surgery. Even if the patient groups are not homogeneous in all respects, there are many arguments in favor of the ileal neobladder
as the urinary diversion of choice.
1.Introduction
Radical cystectomy with bilateral lymphadenectomy and
subsequenturinarydiversionisregardedasthegoldstandard
treatmentformuscle-invasivebladdercancerwithoutdetect-
able hematogenous or lymphogenous metastases [1, 2]. The
intervention should be preceded by detailed patient counsel-
ing on the advantages and disadvantages of diﬀerent types
of urinary diversion. While carefully considering oncological
safety as well as early and late complications, physicians aim
to individually determine what type of urinary diversion
interferes least with the patient’s personal lifestyle in order to
achieve the best possible quality of life and overall treatment
outcome in each particular case [3]. The advantages of
continent urinary diversion are evident [4–6], though some
studies have expressed the opinion that noncontinent uri-
nary diversions are superior concerning potential advantages
such as a faster and easier surgical technique, fewer com-
plications, a lower reoperation rate, and thus a reduced mor-
bidity [7, 8]. Taking these objections into account, the aim
of this investigation was to critically evaluate the advantages
and disadvantages of both procedures in order to have a con-
temporary basis for patient counseling.
2. Patients andMethods
2.1. Patient Population. From January 1993 to August 2007,
301 patients with bladder cancer underwent radical cystec-
tomy with subsequent urinary diversion in the Department
of Urology at Charit´ e Campus Benjamin Franklin. The
patientpopulationcomprised225men(75%)and76women
(25%). The types of urinary diversion were as follows: ileal2 ISRN Urology
Table 1: Demographic and pathological characteristics.
Characteristics
Ileal conduit
Median (interquartile range)
abs. incidence/n, rel. (%)
Ileal neobladder
Median (interquartile range)
abs. incidence/n, rel. (%)
Number 146 115
Age 70 (64–75) 62 (56–66)
Gender
male 98/146 (67%) 110/115 (96%)
female 48/146 (33%) 5/115 (4%)
Comorbidity gradea 3 (2-3) 2 (2-3)
Pathological tumor stageb
organ conﬁned
≤pT2, pN0 46/145 (32%) 65/115 (57%)
non-organ conﬁned
≥pT3, pN0 51/145 (35%) 30/115 (26%)
Lymph node-
positive pN+ 48/145 (33%) 20/115 (17%)
Adjuvant therapy
Chemotherapy 34/146 (24%) 29/115 (20%)
Radiation therapy 3/146 (2%) 3/115 (3%)
Data on relapse
(number of patients) 100 80
Relapse 34/100 (34%) 21/80 (26%)
aU test; P = 0.041.
b2-sided χ2 test, P<0.001.
conduit in 146 cases (49%), ileal neobladder in 115 (38%),
Mainz pouch I in 25 (8%), ureterocutaneostomy 10 (3%),
and other diversions in 5 cases (1.7%). To enable statistical
assessment of patient populations comparable in size, the
study focuses on the analysis of ileal conduit (group 1) and
ileal neobladder (group 2) urinary diversions. Data were
retrospectively collected from the clinical records. A written
inquiry was conducted on the quality of life. The inquiry was
addressed to all patients who underwent radical cystectomy
for primary bladder cancer from 1993 to 2007 and for whom
there were no death data. Patients whose further clinical
course was incompletely documented received a written
inquiry regarding relapse. Comorbidity was assessed using
the Charlson Comorbidity Index [9], which is weighted and
takes into account the number and severity of comorbidities.
Patient and tumor characteristics are summarized in Table 1.
All early-onset complications were recorded, categorized,
and then further grouped into categories as outlined in
Table 2.
2.2. Radical Cystectomy and Urinary Diversion. Radical cys-
tectomy and, if chosen, the ileal neobladder were carried
out applying the technique published by Hautmann et al.
[10]. Contradictions for continent urinary diversion were
impaired renal function (serum creatinine >2mg/dL),severe
hepatic dysfunction, and intestinal disease/tumor manifesta-
tion as well as tumor invasion in the urethral margin. Ileal
conduit (Wallace I) was conducted in the standard fashion
using the minimum amount of ileum.
2.3. Postoperative Course. Patients were postoperatively
managed in the ICU and recovery room. Further post-
operative management was carried out on the urological
ward according to our standardized clinical care pathways
for cystectomy. This involved removal of the gastric tube
immediately after surgery, and standard mobilization and
standard nutritional buildup. On the ﬁrst and second post-
operative days, patients received an increase of liquid food
(up to 500mL water, up to four cups of yogurt). A gradual
buildup with solid food components and full mobilization
were initiated on the third postoperative day. All occurrences
requiringasurgicalinterventionormedicationwereassessed
as a complication. Ileus was deﬁned as postoperative nausea
or vomiting associated with abdominal distension requiring
cessation of oral intake and intravenous ﬂuid support and/or
nasogastric tube (NGT) placement by postoperative day 5
resulting in patient fasting with or without NGT placement
or antiemetic medication administration.
2.4. Questionnaire on Quality of Life. Quality of life was
analyzed using the EORTC QLQ-C30 questionnaire [11].
This was supplemented by the QLQ-BLM30 module of the
EORTC, which was developed speciﬁcally for patients with
muscle-invasive bladder cancer. QLQ-BLM30 has completed
Phase 3 of the module development and was provided by
the EORTC for this investigation (Dr. N. Aaronson, Project
Leader, The Netherlands Cancer Institute, Department of
Psychosocial Research and Epidemiology, Plesmanlaan 121,
1066 CX Amsterdam, The Netherlands). The questionnairesISRN Urology 3
Table 2: Early complications.
Early-onset complications
Ileal conduit
abs. incidence/n
rel. incidence (%)
Ileal neobladder
abs. incidence/n
rel. incidence (%)
Number of patients 146 115
Gastrointestinal 10/145 (6.9%) 19/115 (16.5%)
ileusa 8/145 (5.5%) 17/115 (14.8%)
rectal injury 2/145 (1.4%) 2/115 (1.7%)
Infectious 19/145 (13.1%) 14/115 (12.2%)
sepsis 13/145 (9.0%) 9/115 (7.8%)
intraabdominal/pelvic abscess 6/145 (4.1%) 5/115 (4.3%)
Wound 30/.146 (20.7%) 18/115 (15.7%)
Infection/dehiscence 30/.146 (20.7%) 18/115 (15.7%)
Urinary tract leakage (urinoma) 3/145 (2.1%) 8/115 (7.0%)
Pulmonary 19/145 (13.1%) 11/115 (9.6%)
pneumonia 19/145 (13.1%) 11/115 (9.6%)
Thromboembolic 10/145 (6.9%) 2/115 (1.7%)
thrombosis 6/145 (4.1%) 1/115 (0.9%)
pulmonary artery embolism 4/145 (2.8%) 1/115 (0.9%)
Lymphocele 10/145 (6.9%) 8/115 (7.0%)
Reoperations 25/146 (17.1%) 12/115 (10.4%)
Overall complication rateb 69.1% 69.6%
aFisher’s exact test P = 0.018.
bPercentage of patients with one or more complications.
were analyzed for the QLQ-C30 questions according to
the instructions in the EORTC scoring manuals [12]. The
EORTC scoring system was also used to assess the QLQ-
BLM30 module.
2.5. Statistical Data Analysis. SPSS 16.0 software was used
for statistical analysis. All interval scale data were assessed
by the Kolmogorov-Smirnov test with Liliefors signiﬁcance
correction for deviations from normal distribution. Signif-
icance was determined by using either the two-sided t test,
the two-sided Mann-Whitney U test, Pearson’s chi-square
test, or Fisher’s exact test. The Kaplan-Meier procedure with
the log-rank test was used for survival statistics. An error
probability of P<0.05 was deﬁned as the signiﬁcance limit.
3. Results
3.1. Patient Collective and Followup. The median age was 70
years (interquartile range, 64–75) in patients with an ileal
conduit (group1) and 62 years (56–66) in group 2 patients
(P<0.001). The mean observation time was 33.2 ± 32.77
months in group 1 and 50.6 ± 44.98 months in group 2.
Median comorbidity grade in patients with ileal conduit
and ileal neobladder was 3 (range 2-3) and 2 (range 2-3),
respectively (U-test; P = 0.041). The pathological tumor
stages were evaluated by assignment to three prognostic
groups: organ conﬁned (≤pT2, pN0), non-organ conﬁned
(≥pT3, pN0), and lymph node positive (pN+) [13, 14]. This
distribution diﬀers to a highly signiﬁcant degree between
groups 1 and 2 (2-sided χ2 test, P<0.001). No patient in
either group received neoadjuvant chemotherapy or radia-
tiontherapy.Adjuvantchemotherapywasadministeredin34
(24%) patients in the ileal conduit group and in 29 (20%)
in the orthotopic diversion group (P = 0.509). Adjuvant
radiotherapy was administered in 3 patients of each group
(P = 0.849). Patients’ characteristics and their individual
therapeutic approaches are summarized in Table 1.
3.2. Early Complications. All in-hospital events were assessed
as early complications (Table 2). The most frequent compli-
cations in group 1 were wound related (20.7%), infectious
(13.1%), and pulmonary (13.1%), while gastrointestinal
(16.5%), wound-related (15.7%), and infectious (12.2%)
c o m p l i c a t i o n sw e r em o s tc o m m o ni ng r o u p2 .T h et w o
groups diﬀered signiﬁcantly with regard to the occurrence
of postoperative ileus (P = 0.0184. Fisher’s exact test) but
not with regard to any of the other complications measured
(Table 2). Perioperative mortality (within the ﬁrst 30 days
after surgery) was 4.1% in group 1 and 1.7% in group 2
(P = 0.47, Fisher’s exact test). The reoperation rate was
17.1% in group 1 and 10.4% in group 2 (χ2 test, P = 0.124).
3.3. Quality of Life. In 2008 we sent the quality of life ques-
tionnaires to 126 surviving patients, of whom 58 completed
and returned the survey for a 46% response rate. Data
obtained with the QLQ-C30 questionnaire disclosed three
signiﬁcant diﬀerences between patients of group 1 and 2
(Table 3). The global health status/quality of life (72.3±19.5,4 ISRN Urology
Table 3: QLQ-C30.
QLQ-C30
Ileal conduit
Mean ± standard dev.
Median (interquartile range)
n = number of cases
Ileal neobladder
Mean ± standard dev.
Median (interquartile range)
n = number of cases
Functional scales
Global health status/quality of lifea
58.0 ±25.37 2 .3 ±19.5
58.3 (33.3–83.3) 70.8 (56.2–85.4)
n = 23 n = 34
Physical functioningb
65.8 ±29.48 2 .6 ±19.9
70 (33.3–93.3) 93.3 (71.6–100)
n = 24 n = 34
Role functioning
63.8 ±31.17 6 .0 ±27.9
66.7 (33.3–100) 83.3 (50–100)
n = 24 n = 34
Emotion functioning
72.2 ±22.38 1 .1 ±22.3
70.8 (52.1–91.7) 87.5 (66.7–100)
n = 24 n = 34
Cognitive functioning
77.8 ±22.98 3 .3 ±20.5
83.3 (54.2–100) 83.3 (66.7–100)
n = 24 n = 34
Social functioning
65.3 ±32.27 0 .1 ±33.0
83.3 (33.3–95.8) 75 (45.8–100)
n = 24 n = 34
Symptoms scales
Fatigue
37.5 ±28.12 6 .0 ±28.3
33.3 (11.1–63.9) 16.7 (0–55.6)
n = 24 n = 34
Nausea and vomiting
9.7 ±20.23 .4 ±12.8
0 (0–12.5) 0 (0-0)
n = 24 n = 34
Pain
26.4 ±31.81 8 .6 ±34.0
8.3 (0–50) 0 (0–33.3)
n = 24 n = 34
Single items
Dyspnoea
37.5 ±35.92 7 .5 ±37.1
33 (0–66.7) 0 (0–41.7)
n = 24 n = 34
Insomnia
29.2 ±31.62 1 .6 ±27.1
33.3 (0–66.7) 0 (0–33.3)
n = 24 n = 34
Appetite loss
18.1 ±31.16 .9 ±17.9
0 (0–33.3) 0 (0-0)
n = 24 n = 34
Constipation
22.2 ±30.61 1 .8 ±19.9
0 (0–33.3) 0 (0–33.3)
n = 24 n = 34ISRN Urology 5
Table 3: Continued.
QLQ-C30
Ileal conduit
Mean ± standard dev.
Median (interquartile range)
n = number of cases
Ileal neobladder
Mean ± standard dev.
Median (interquartile range)
n = number of cases
Diarrhoeac
4.2 ±14.92 3 .5 ±31.3
0 (0-0) 0 (0–33.3)
n = 24 n = 34
Financial diﬃculties
25.0 ±35.82 0 .6 ±32.8
0 (0–66.7) 0 (0–41.7)
n = 24 n = 34
at-test; P = 0.019.
bU test; P = 0.018.
cU test; P = 0.004.
EORTC QLQ-C30 results of this study. The questionnaire assesses cancer-speciﬁc QOL. For all the questions, a scale from 1 to 4 was used
(1: not at all, 2: a little, 3: quite a bit, 4: very much). All scores were linearly transformed such that all scales range from 0 to 100. For the six
functional items, the higher score represents a higher level of functioning and for the symptoms/single items, a higher score means a higher
level of symptomatology/problems.
n = 34 versus 58.0 ± 25.3; n = 23; P = 0.019, 2-sided t-test;)
and physical functioning (82.6 ± 19.9, n = 34 versus 65.8 ±
29.4, n = 24; P = 0.018, 2-sided U test) were rated markedly
higher by patients with ileal neobladder (group 2). All other
functions (role functioning, emotional, cognitive, and social
functioning) are also better performed by patients with ileal
neobladderthanbythosewithilealconduitbutdidnotreach
statistical signiﬁcance. With one exception, all symptom
scalesshowhighervaluesforpatientswithilealconduitwith-
out statistical signiﬁcance (group 1). Diarrhoea is the only
symptom that occurs signiﬁcantly more often in patients
with ileal neobladder than in those with ileal conduit (25.5±
31.3, n = 24 versus 4.2 ± 14.9, n = 34); P = 0.004, 2-sided
U test). The two patient groups did not diﬀer signiﬁcantly
in the results of the QLQ-BLM30 module (Table 4). Sexual
functioning could not be analyzed because an altogether
insuﬃcient number of patients answered these questions.
3.4. Overall Survival and Relapse. In 180 patients (69.0%)
suﬃcient follow-up data were available for Kaplan-Meier
analysis. OS diﬀered signiﬁcantly between the ileal neoblad-
der and the ileal conduit group (log-rank test; P<0.001).
The estimated 5-year survival was 46% and 67% in groups
1 and 2, respectively. The estimated 10-year survival was
30% in group 1 and 56% in group 2. Survival correlated
signiﬁcantly with the prognostic group (pathological tumor
stage) in the total patient population (P<0.001, log-rank
test). For the entire study population the 5-year survival
probability was highest in patients with an organ-conﬁned
(≤pT2, pN0) tumor (82%) and markedly lower in those
with a non-organ-conﬁned (≥pT3, pN0) tumor (48%) or
a lymph-node-positive (pN+) tumor (28%), respectively
(P<0.001). When 5-year OS was compared according
to prognostic groups, patients with ileal neobladder had a
signiﬁcantly higher survival in patients with organ-conﬁned
(≤pT2, pN0) tumors (80%) than those with ileal conduit
(70%) (log-rank test; P = 0.03). In the other two prognostic
groups, that is, ≥pT3, pN0 patients and pN+ patients, the
5 year OS rate did not diﬀer signiﬁcantly between patients
with either urinary diversion. The survival probability was
not inﬂuenced by the diﬀerent comorbidity grades of the
study population (group 1, P = 0.879; group 2, P = 0.474).
The relapse rate was 34% in group 1 and 26% in group 2 (2-
sided χ2 test; P = 0.26, Table 1). Systemic relapses occurred
in both groups (group 1: 61.3%; group 2: 40%; 2-sided χ2
test; P = 0.23). Local relapse occurred in 5 patients in group
1 and in 7 patients in group 2 (2-sided χ2 test; P = 0.23).
4. Discussion
As the risk for developing any type of complications in
both sexes ranges from 16% to 66%, radical cystectomy with
neobladderreconstructionrepresentsamajor,complication-
prone surgery [15–17]. This wide range of complication
rates reported by diﬀerent studies is mainly explained by the
fact that various complications are not surveyed in detail
in diﬀerent standardized reporting systems, and studies
are thus diﬃcult to compare. In our series, ileus occurred
signiﬁcantly more often in patients with ileal neobladder.
In contrast to our data, Parekh et al. [5] found a higher
incidence of postoperative paralytic ileus in patients with
ileal conduit (7.4%) than in those with neobladder (2.6%).
Nieuwenhuijzen et al. reported a very similar incidence of
postoperative ileus for both urinary diversions [15]. The
heterogeneous results of the published studies suggest that
the reason for postoperative ileus is manifold and can occur
regardless of the type of urinary diversion [8]. However,
one explanation for the higher incidence of colonic motility
disorders in the ileal neobladder group might be leakage of
urine from the not-yet fully healed neobladder in the early
postoperative phase [16].
Many diﬀerent questionnaires are used to measure the
quality of life in oncological urology (e.g., self-developed
questionnaires, SF-36, FACT-G, and QLQ-C30). Thus it is
very diﬃcult to achieve comparability of results [18]. Not
all the questionnaires have been validated, and they diﬀer6 ISRN Urology
Table 4: QLQ-BLM30
QLQ-BLM30
Ileal conduit
Mean ± standard dev.
Median (interquartile range)
n = number of cases
Ileal neobladder
Mean ± standard dev.
Median (interquartile range)
n = number of cases
Urinary symptom
33.6 ±26.3
33.3 (9.5–52.4)
n = 33
Urostomy problem
25.6 ±22.0
19.4 (6.9–43.8)
n = 24
Single catheter use problem
0 ±0 6.7 ±14.9
0 (0-0) 0 (0–16.7)
n = 1 n = 5
Future perspective
39.1 ±33.8 24.3 ±27.9
33.3 (11.1–66.7) 11.1 (0–44.4)
n = 23 n = 32
Abdominal bloating and
ﬂatulence
28.3 ±25.8 29.7 ±31.0
33.3 (0–50.0) 16.7 (0–50)
n = 23 n = 32
Body image
34.1 ±32.3 33.5 ±28.2
22.2 (11.1–55.6) 33.3 (11.1–55.6)
n = 23 n = 32
Sexual functioning no available data no available data
EORTC QLQ-BLM30 results of this study. The questionnaire is a phase-3 module that speciﬁcally evaluates the impact of radical cystectomy
and reconstructive surgery in terms of health-related quality of life. For all the questions, a scale from 1 to 4 was used (1: not at all, 2: a little,
3: quite a bit, 4: very much). All scores were linearly transformed such that all scales range from 0 to 100. For the symptoms/single items, a
higher score means a higher level of symptomatology/problems.
considerablyinsomeofthetopicscovered.Anotherdiﬃculty
lies in the fact that quality of life is a multidimensional
concept incorporating diﬀerent domains that are weighted
by their importance to the individual and may change over
time [19]. In oncological urology, quality of life is usually
assessed in retrospective studies where only postoperative
dataareavailableinmostcases[20–22].Aninteractioncould
even be demonstrated between patients and the investigating
institution, which is hypothetically attributed to heroization
and idealization of the attending urologists [23].
We used the validated EORTC QLQ-C30 questionnaire
with the QLQ-BLM30 module for the present investigation
in order to exclude as many of the above-mentioned
problemsaspossible.AnalysisoftheQLQ-C30questionnaire
showed that patients with ileal conduit (group 1) diﬀered
signiﬁcantly from those with ileal neobladder (group 2) in
the assessment of the general health status and quality of
life and in the mastery of physical functions. These ﬁndings
were in line with the results obtained by Hobisch et al. using
the same questionnaire [6]. In our series the occurrence of
diarrhoea diﬀered signiﬁcantly between patients of group
1 and 2 favouring patients with an ileal conduit. This ob-
servation was not experienced by other studies with the
QLQ-C30 questionnaire that show no signiﬁcant diﬀerences
between the two surgical procedures [24, 25].
In our study, the assessment of the QLQ-BLM30 module
showed no signiﬁcant diﬀerences between patients of group
1and2,whichalsocoincideswiththeresultsofanotheranal-
ysis[24].Nevertheless,theapplicationoftheSF-36question-
naire in other studies comparing patients with orthotopic
diversionversusilealconduityieldedaheterogeneouspicture
in terms of the subjective quality of life assessment [26–29].
The 5-and 10-year overall survival was analyzed to
be signiﬁcantly higher in patients who received an ileal
neobladder compared to those with an ileum conduit (P<
0.001). However, this observation has to be interpreted with
great caution since both groups are heterogeneous in age,
comorbidity, and especially in distribution to well-known
prognostic parameters such as tumor stage and lymph node
status (P<0.001, 2-sided χ2 test). This could, of course, also
account for the diﬀerences in postoperative quality of life.
The heterogeneity of the study groups clearly demonstrates
that although the patient has great inﬂuence on the deﬁnite
type of diversion, the surgeons’ preference and information
remain the important determinant of choice, considering
the diﬀerences in age and comorbidity between the patientsISRN Urology 7
opting for an ileal conduit and continent diversions. Other
limitations of our study are certainly its retrospective design
andheterogeneousfollowup,partlywithalongfollow-uppe-
riod. Obviously perioperative patient care and methods of
patient counseling have been steadily improved and changed
over this 14-year period and might have aﬀected our results.
Due to the nonrandomized retrospective nature of our study
based on two heterogeneous cohorts, prospective random-
ized trails would be needed to prove real value. However, we
are aware that it is extremely unlikely that a prospective ran-
domized trial comparing ileal conduit to neobladder can and
will ever be realized.
5. Conclusions
Cystectomy with any type of diversion remains a compli-
cation-prone surgery. Even if the patient groups are not
homogeneous in most respects, there are many arguments
in favor of the ileal neobladder as the urinary diversion of
choice whenever technically feasible and oncologically justi-
ﬁed.
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